A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China

NCT07198620 · tracked via the Priya Life Science China tracker

Sponsor

Guangdong Association of Clinical Trials

Phase

Observational

Started

2025-10-01

Last updated

2025-09-30

Condition(s) studied

Lung Cancer (NSCLC)

Study summary

This study is a retrospective, multicenter, real-world investigation designed to evaluate the efficacy and safety of IBI-351 in Chinese patients with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation in a real-world setting. A total of 600 patients with KRAS G12C-mutated advanced NSCLC who received treatment with IBI-351 between August 2024 and August 2025 will be retrospectively enrolled. Descriptive statistical methods will be used to summarize the baseline characteristics, demographic data, and medication profiles of the subjects. Unless otherwise specified, continuous data will be described using counts, means, standard deviations, maximum and minimum values, and medians; categorical data will be summarized using counts and percentages. The incidence of adverse events (AEs) and serious adverse events (SAEs) will be aggregated and presented as the number and percentage of affected subjects, and all AEs will be listed in detail. The primary endpoint is the objective response rate (ORR) as assessed by investigators, and descriptive statistics for ORR will be provided. For the secondary endpoints, progression-free survival (PFS) and overall survival (OS), Kaplan-Meier (K-M) analysis will be performed to estimate median values and corresponding 95% confidence intervals (CIs), and K-M curves will be generated accordingly.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Voluntarily participate in the study and provide signed informed consent. * Have histologically or cytologically confirmed locally advanced or metastatic NSCLC, classified according to the IASLC 8th edition Lung Cancer TNM Staging System. * Carry a confirmed KRAS G12C mutation via molecular testing. * Have received at least one dose of oral IBI-351 treatment between August 2024 and August 2025. Exclusion Criteria: * Histologically or cytologically confirmed mixed NSCLC with a predominant small cell or squamous cell carcinoma component. * Presence of EGFR sensitizing mutations, ALK rearrangements, ROS1 fusions, or other genomic alterations for which NMPA has approved first-line NSCLC therapies.

Primary outcome measure(s)

Objective response rate — At least 12 months retrospectively
The proportion of patients achieving complete and partial response after treatment, measured according to RECIST v1.1 criteria

Trial sites (1)

Facility	City	Region	Status
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,	Guangzhou	Guangdong

More Guangdong Association of Clinical Trials trials in China

MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) Active, not recruiting

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC Recruiting

Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study Recruiting

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases Active, not recruiting

RGL-270 + ICI in Advanced NSCLC Recruiting

Other trials for the same condition

Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy Recruiting

Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy Starting soon

Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines Active, not recruiting

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer Recruiting

Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07198620 on ClinicalTrials.gov ↗ ← All trials in China